Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer-Reference-Cited by-同舟云学术

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer

Published:2019-12-01 Issue:12 Volume:5 Page:1731
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Liu Joyce F.¹,Herold Christina²,Gray Kathryn P.³,Penson Richard T.⁴,Horowitz Neil¹,Konstantinopoulos Panagiotis A.¹,Castro Cesar M.⁴,Hill Sarah J.⁵,Curtis Jennifer¹,Luo Weixiu³,Matulonis Ursula A.¹,Cannistra Stephen A.⁶,Dizon Don S.⁴⁷

Affiliation:

1. Division of Gynecologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

2. Division of Breast Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

3. Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts

4. Department of Medical Oncology, Massachusetts General Hospital, Boston

5. Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts

6. Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts

7. Department of Medical Oncology, Lifespan Cancer Institute, Rhode Island Hospital, Providence

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2752504/jamaoncology_liu_2019_oi_190068.pdf

Reference34 articles.

1. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.;Zhang;N Engl J Med,2003

2. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.;Hwang;Gynecol Oncol,2012

3. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.;Hamanishi;Proc Natl Acad Sci U S A,2007

4. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer.;Hamanishi;J Clin Oncol,2015

5. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: interim results from the phase 2 KEYNOTE-100 study;Matulonis;Ann Oncol

Cited by 156 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach;Nature Reviews Clinical Oncology;2024-09-04

2. Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial;The Lancet Oncology;2024-09

3. The Role of Immunotherapy in the Treatment of Gynecologic Cancers: A Systematic Review;Cureus;2024-07-29

4. Targeting cytokine and chemokine signaling pathways for cancer therapy;Signal Transduction and Targeted Therapy;2024-07-22

5. Navigating immunotherapy for ovarian cancer: current landscape and future perspectives;Journal of Cancer Metastasis and Treatment;2024-06-26